Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Anemia 38Neoplasms 18Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma 5Neoplasms, Plasma Cell 4Multiple Myeloma 4Lung Neoplasms 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precancerous Conditions 3Mycosis Fungoides 3Monoclonal Gammopathy of Undetermined Significance 3Lymphoproliferative Disorders 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Follicular 3Leukemia, Prolymphocytic 3Leukemia, Large Granular Lymphocytic 3Immunoglobulin Light-chain Amyloidosis 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Hematologic Neoplasms 3

Interventions

Paclitaxel 2tremelimumab 1pegfilgrastim 1durvalumab 1Taxes 1Sunitinib 1Lapatinib 1Imatinib Mesylate 1Ifosfamide 1Darbepoetin alfa 1Cisplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Dysgerminoma × Darbepoetin alfa × Clear all
NCT00204633 2009-02-16

Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)

University Hospital Tuebingen

Phase 2 Completed
108 enrolled

Dysgerminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡